Pacritinib

Summary

Pacritinib (CHEMBL2035187) is an approved small-molecule EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor (ATC L01EJ03) targeting FLT3, JAK1, and JAK2; indicated across 19 conditions including neoplasm and primary myelofibrosis; with CIViC clinical evidence for 6 variant-indication associations (e.g. FLT3 ITD in acute myeloid leukemia).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01EJ03
• Targets: 4 (FLT3, JAK1, JAK2…)
• Indications: 19 conditions
• Clinical trials: 51
• Precision-oncology evidence (CIViC): 6 variant–indication associations
• Chemistry: 472.6 Da · C28H32N4O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2035187
Name	Pacritinib
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	46216796
ChEBI	CHEBI:231350
ATC	L01EJ03
Molecular formula	C28H32N4O3
Molecular weight	472.6
InChIKey	HWXVIOGONBBTBY-ONEGZZNKSA-N

SMILES: C1CCN(C1)CCOC2=C3COC/C=C/COCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2

IUPAC name: (16E)-11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(24),2(27),3,5,8(26),9,11,16,21(25),22-decaene

ChEBI definition: An azamacrocycle with formula C28H32N4O3. It is a Janus kinase inhibitor and its citrate salt is approved for the treatment of intermediate or high risk, primary or secondary myelofibrosis.

Pharmacological roles (ChEBI): EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, antineoplastic agent, apoptosis inducer, anti-inflammatory agent.

Also known as: ONX-0803, Pacritinib, Sb-1518, SB-1518, SB1518, pacritinib, PACRITINIB, PACRITINIB (SB1518), Pacritinib (SB1518)

Parent form; salt/anhydrous children: CHEMBL5095049

Patent coverage: 1,313 distinct patent families (3,345 SureChEMBL compound mentions), from 6 matched compound structure(s). One matched structure accounts for 3,220 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
FLT3	fms related receptor tyrosine kinase 3	Inhibition	7.66	0.9%	P36888
JAK1	Janus kinase 1	Inhibition	5.89	2.8%	P23458
JAK2	Janus kinase 2	Inhibition	7.64	0.7%	O60674
JAK3	Janus kinase 3	Inhibition	6.28	0.6%	P52333

Broader ChEMBL bioactivity targets: 51 (assay-derived). Sample: Serine/threonine-protein kinase TAO2, Serine/threonine-protein kinase ICK, Tyrosine-protein kinase JAK2, Macrophage colony-stimulating factor 1 receptor, Platelet-derived growth factor receptor beta, Receptor-type tyrosine-protein kinase FLT3, Cyclin-dependent kinase 2/cyclin A, Tyrosine-protein kinase JAK3, Aurora kinase B, Mitogen-activated protein kinase 8.

Bioactivity

ChEMBL activities: 107 potent at pChembl ≥ 5 of 111 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
JAK2	9	IC50	1	nM	CHEMBL_ACT_16844229
STK11	8.52	Kd	3	nM	CHEMBL_ACT_17940797
NQO2	8.4	Kd	4	nM	CHEMBL_ACT_17922432
FLT3	8.22	IC50	6	nM	CHEMBL_ACT_12151323
JAK2	8.22	IC50	6	nM	CHEMBL_ACT_24975332
FLT3	8.22	IC50	6	nM	CHEMBL_ACT_26312576
FLT3	8.22	IC50	6	nM	CHEMBL_ACT_26327143
FLT3	8.19	IC50	6.4	nM	CHEMBL_ACT_24975318
JAK2	8.18	Kd	6.6	nM	CHEMBL_ACT_25839816
FLT3	8.1	IC50	8	nM	CHEMBL_ACT_26327153
JAK2	8.05	Kd	8.9	nM	CHEMBL_ACT_25839917
FLT3	7.92	IC50	12	nM	CHEMBL_ACT_24975333
JAK2	7.85	IC50	14	nM	CHEMBL_ACT_25839856
JAK3	7.74	IC50	18.3	nM	CHEMBL_ACT_24975331
FLT3	7.74	IC50	18.3	nM	CHEMBL_ACT_24975334
JAK2	7.72	IC50	19	nM	CHEMBL_ACT_12151324
JAK2	7.72	IC50	19	nM	CHEMBL_ACT_26312572
FLT3	7.7	IC50	20	nM	CHEMBL_ACT_26327150
FLT3	7.66	IC50	22	nM	CHEMBL_ACT_12151360
ACVR1	7.66	Kd	22	nM	CHEMBL_ACT_17880654
JAK2	7.66	IC50	22	nM	CHEMBL_ACT_19067279
FLT3	7.66	IC50	22	nM	CHEMBL_ACT_24862940
FLT3	7.66	IC50	22	nM	CHEMBL_ACT_25683705
FLT3	7.66	IC50	22	nM	CHEMBL_ACT_26123576
FLT3	7.66	IC50	22	nM	CHEMBL_ACT_26312575
FLT3	7.66	IC50	22	nM	CHEMBL_ACT_26327142
FLT3	7.66	IC50	22	nM	CHEMBL_ACT_29252829
JAK2	7.64	IC50	23	nM	CHEMBL_ACT_12153235
FLT3	7.64	IC50	23	nM	CHEMBL_ACT_19067278
JAK2	7.64	IC50	23	nM	CHEMBL_ACT_24788502

Target pathways

Aggregated over 4 target gene(s): FLT3, JAK1, JAK2, JAK3.

Top Reactome pathways

111 total, by targets touching each:

Pathway	Targets	Genes
RAF/MAP kinase cascade	4	FLT3, JAK1, JAK2, JAK3
Cytokine Signaling in Immune system	3	JAK1, JAK2, JAK3
Signal Transduction	3	JAK1, JAK2, JAK3
Disease	3	JAK1, JAK2, JAK3
Immune System	3	JAK1, JAK2, JAK3
Signaling by Interleukins	3	JAK1, JAK2, JAK3
Interleukin-2 family signaling	3	JAK1, JAK2, JAK3
Interleukin-3, Interleukin-5 and GM-CSF signaling	3	JAK1, JAK2, JAK3
Infectious disease	3	JAK1, JAK2, JAK3
MAPK family signaling cascades	3	JAK1, JAK2, JAK3
MAPK1/MAPK3 signaling	3	JAK1, JAK2, JAK3
Interleukin-4 and Interleukin-13 signaling	3	JAK1, JAK2, JAK3
Interleukin-20 family signaling	3	JAK1, JAK2, JAK3
Interleukin receptor SHC signaling	3	JAK1, JAK2, JAK3
Potential therapeutics for SARS	3	JAK1, JAK2, JAK3
SARS-CoV Infections	3	JAK1, JAK2, JAK3
Viral Infection Pathways	3	JAK1, JAK2, JAK3
Interleukin-6 signaling	2	JAK1, JAK2
MAPK3 (ERK1) activation	2	JAK1, JAK2
RAF-independent MAPK1/3 activation	2	JAK1, JAK2
MAPK1 (ERK2) activation	2	JAK1, JAK2
Interleukin-7 signaling	2	JAK1, JAK3
Interleukin-12 family signaling	2	JAK1, JAK2
Interleukin-6 family signaling	2	JAK1, JAK2
IL-6-type cytokine receptor ligand interactions	2	JAK1, JAK2
Interferon gamma signaling	2	JAK1, JAK2
Regulation of IFNG signaling	2	JAK1, JAK2
Interleukin-15 signaling	2	JAK1, JAK3
Interleukin-35 Signalling	2	JAK1, JAK2
Interleukin-9 signaling	2	JAK1, JAK3

Dominant GO biological processes

GO term	Targets
cytokine-mediated signaling pathway	4
protein phosphorylation	4
regulation of apoptotic process	3
cell surface receptor signaling pathway via JAK-STAT	3
cell differentiation	3
intracellular signal transduction	3
growth hormone receptor signaling pathway via JAK-STAT	3
regulation of cell-cell adhesion	3
positive regulation of cell population proliferation	2
B cell differentiation	2
positive regulation of tyrosine phosphorylation of STAT protein	2
positive regulation of MAPK cascade	2
protein autophosphorylation	2
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	2
interleukin-15-mediated signaling pathway	2

Indications & clinical

Indications

19 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
primary myelofibrosis	2	MONDO:0009692	EFO:0002430
leukemia	2	MONDO:0005059	EFO:0000565
Hodgkins lymphoma	2	MONDO:0004952	EFO:0000183
acute myeloid leukemia	2	MONDO:0018874	EFO:0000222
mantle cell lymphoma	2	MONDO:0018876	EFO:1001469
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
lymphoma	2	MONDO:0005062	EFO:0000574
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
B-cell chronic lymphocytic leukemia	1	MONDO:0004948	EFO:0000095
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060
graft versus host disease	1	MONDO:0013730	MONDO:0013730
breast neoplasm	1	MONDO:0021100	MONDO:0007254
liver disorder	1	MONDO:0005154	EFO:0001421
myelodysplastic syndrome	1	MONDO:0018881	EFO:0000198
chronic myelomonocytic leukemia	1	MONDO:0020311	MONDO:0020311

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 51.

Phase distribution

Phase	Trials
PHASE2	23
PHASE1	14
PHASE1/PHASE2	10
PHASE3	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03165734	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT01773187	PHASE3	TERMINATED	Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
NCT02055781	PHASE3	TERMINATED	Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
NCT03645824	PHASE2	ACTIVE_NOT_RECRUITING	Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)
NCT04282187	PHASE2	RECRUITING	Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
NCT04520269	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)
NCT04858256	PHASE2	RECRUITING	Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
NCT05531786	PHASE1/PHASE2	RECRUITING	Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
NCT05980806	PHASE2	RECRUITING	A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT06052618	PHASE2	RECRUITING	Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
NCT06159491	PHASE1/PHASE2	RECRUITING	Pacritinib in CMML
NCT06303193	PHASE1/PHASE2	RECRUITING	Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
NCT06782373	PHASE2	RECRUITING	A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06986174	PHASE2	RECRUITING	A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
NCT07033598	PHASE2	RECRUITING	Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
NCT07148947	PHASE2	RECRUITING	Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
NCT07226713	PHASE2	NOT_YET_RECRUITING	Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors
NCT07387354	PHASE1/PHASE2	NOT_YET_RECRUITING	Pacritinib With Aza for Upfront Myelodysplastic Syndrome
NCT07394153	PHASE2	RECRUITING	Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia
NCT07447817	PHASE2	NOT_YET_RECRUITING	Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
NCT00719836	PHASE1/PHASE2	COMPLETED	A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
NCT00745550	PHASE1/PHASE2	COMPLETED	A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
NCT01263899	PHASE2	COMPLETED	A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
NCT01436084	PHASE2	TERMINATED	SB1518 for Patients With Myelodysplastic Syndrome (MDS)
NCT01620216	PHASE2	TERMINATED	Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
NCT02277093	PHASE2	TERMINATED	Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer
NCT02410551	PHASE2	TERMINATED	Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
NCT02469415	PHASE2	TERMINATED	Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
NCT02532010	PHASE2	TERMINATED	Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML
NCT02584777	PHASE2	WITHDRAWN	A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis
NCT02677948	PHASE1/PHASE2	WITHDRAWN	Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT02891603	PHASE1/PHASE2	COMPLETED	A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
NCT04404361	PHASE2	TERMINATED	PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
NCT04635059	PHASE2	TERMINATED	Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer
NCT04884191	PHASE2	COMPLETED	Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
NCT06516887	PHASE1/PHASE2	TERMINATED	Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma
NCT06218628	PHASE1	RECRUITING	Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
NCT06538181	PHASE1	RECRUITING	Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
NCT06675123	PHASE1	RECRUITING	Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT00741871	PHASE1	COMPLETED	A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies

Clinical evidence (CIViC)

Variant × indication × effect (6 predictive associations from 6 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
FLT3 ITD	Acute Myeloid Leukemia	Sensitivity/Response	Pacritinib	CIViC B	EID9217
EGFR G598V	Glioblastoma	Sensitivity/Response	Pacritinib + Afatinib	CIViC D	EID8235
EGFR G598V	Glioblastoma	Sensitivity/Response	Erlotinib + Pacritinib	CIViC D	EID8236
EGFR G598V	Glioblastoma	Sensitivity/Response	Pacritinib + Lapatinib	CIViC D	EID8261
EGFR G598V	Glioblastoma	Sensitivity/Response	Pacritinib + Osimertinib	CIViC D	EID8284
EGFR VIII	Glioblastoma	Sensitivity/Response	Pacritinib + Afatinib	CIViC D	EID8192

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

178 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
AFATINIB	ChEMBL + PubChem	Phase 4 (approved)	FLT3, JAK1, JAK2, JAK3
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	FLT3, JAK1, JAK2, JAK3
GEFITINIB	ChEMBL + PubChem	Phase 4 (approved)	FLT3, JAK1, JAK2, JAK3
PAZOPANIB	ChEMBL + PubChem	Phase 4 (approved)	FLT3, JAK1, JAK2, JAK3
CERITINIB	ChEMBL	Phase 4 (approved)	FLT3, JAK1, JAK2, JAK3
ENTRECTINIB	ChEMBL	Phase 4 (approved)	FLT3, JAK1, JAK2, JAK3
FEDRATINIB	ChEMBL	Phase 4 (approved)	FLT3, JAK1, JAK2, JAK3
FILGOTINIB	ChEMBL	Phase 4 (approved)	FLT3, JAK1, JAK2, JAK3
MIDOSTAURIN	ChEMBL	Phase 4 (approved)	FLT3, JAK1, JAK2, JAK3
NINTEDANIB	ChEMBL	Phase 4 (approved)	FLT3, JAK1, JAK2, JAK3
SUNITINIB	ChEMBL	Phase 4 (approved)	FLT3, JAK1, JAK2, JAK3
DOVITINIB	ChEMBL	Phase 3	FLT3, JAK1, JAK2, JAK3
LESTAURTINIB	ChEMBL	Phase 3	FLT3, JAK1, JAK2, JAK3
AT-9283	ChEMBL	Phase 2	FLT3, JAK1, JAK2, JAK3
AZD-1480	ChEMBL	Phase 2	FLT3, JAK1, JAK2, JAK3
CERDULATINIB	ChEMBL	Phase 2	FLT3, JAK1, JAK2, JAK3
R-406	ChEMBL	Phase 2	FLT3, JAK1, JAK2, JAK3
SU-014813	ChEMBL	Phase 2	FLT3, JAK1, JAK2, JAK3
TOZASERTIB	ChEMBL	Phase 2	FLT3, JAK1, JAK2, JAK3
Idelalisib	PubChem	Approved	FLT3, JAK1, JAK2, JAK3
Selumetinib	PubChem	Approved	FLT3, JAK1, JAK2, JAK3
dacomitinib	ChEMBL + PubChem	Phase 4 (approved)	FLT3, JAK1, JAK3
DEUCRAVACITINIB	ChEMBL + PubChem	Phase 4 (approved)	JAK1, JAK2, JAK3
FOSTAMATINIB	ChEMBL + PubChem	Phase 4 (approved)	FLT3, JAK1, JAK2
IMATINIB	ChEMBL + PubChem	Phase 4 (approved)	FLT3, JAK1, JAK2
RITLECITINIB	ChEMBL + PubChem	Phase 4 (approved)	JAK1, JAK2, JAK3
ABROCITINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3
AXITINIB	ChEMBL	Phase 4 (approved)	FLT3, JAK2, JAK3
BARICITINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3
BOSUTINIB	ChEMBL	Phase 4 (approved)	FLT3, JAK2, JAK3
DASATINIB	ChEMBL	Phase 4 (approved)	FLT3, JAK2, JAK3
ERLOTINIB	ChEMBL	Phase 4 (approved)	FLT3, JAK2, JAK3
MOMELOTINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3
PEFICITINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3
PONATINIB	ChEMBL	Phase 4 (approved)	FLT3, JAK1, JAK2
RUXOLITINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3
TOFACITINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3
UPADACITINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3
ABIVERTINIB	ChEMBL	Phase 3	JAK1, JAK2, JAK3
ALVOCIDIB	ChEMBL	Phase 3	FLT3, JAK2, JAK3
BREPOCITINIB	ChEMBL	Phase 3	JAK1, JAK2, JAK3
DEFACTINIB	ChEMBL	Phase 3	FLT3, JAK2, JAK3
DELGOCITINIB	ChEMBL	Phase 3	JAK1, JAK2, JAK3
ITACITINIB	ChEMBL	Phase 3	JAK1, JAK2, JAK3
ATINVICITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3
BMS-911543	ChEMBL	Phase 2	JAK1, JAK2, JAK3
CC-401	ChEMBL	Phase 2	JAK1, JAK2, JAK3
CENISERTIB	ChEMBL	Phase 2	FLT3, JAK2, JAK3
DECERNOTINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3
GANDOTINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3
GOLIDOCITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3
GUSACITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3
IFIDANCITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3
IZENCITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3
NEZULCITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3
NS-018	ChEMBL	Phase 2	JAK1, JAK2, JAK3
OCLACITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3
PELITINIB	ChEMBL	Phase 2	FLT3, JAK2, JAK3
REBASTINIB	ChEMBL	Phase 2	FLT3, JAK1, JAK2
ROPSACITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3